Clearmind announces publication of U.S. patent application on binge behavior

Clearmind Medicine (CMND) announced the publication of a U.S. patent application by the United States Patent and Trademark Office for its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines, such as Palmitoylethanolamide, addressing binge behavior disorders. The patent application stems from Clearmind’s ongoing collaboration with SciSparc (SPRC). This therapy targets multiple binge behaviors, including excessive alcohol consumption binge eating, smoking, compulsive shopping, and problematic sexual conduct. The combination leverages MEAI’s neuroplastic properties to reduce impulsivity and reward-seeking behavior, which, together with PEA, has shown a synergistic pharmacological effect and therefore potentially offering a breakthrough in treating substance use disorders and addictions by presenting a more effective and safer treatment than those available today. This publication builds on Clearmind’s intellectual property portfolio. The Company has filed 13 patents related to its collaboration with SciSparc, focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Preclinical data supports MEAI’s efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.